What is Postpartum Depression?

 Postpartum depression (PPD) is a prevalent and potentially debilitating and life-threatening condition, occurring following ~ 12% of births. Approximately 1 in 8 mothers suffers from PPD in the United States alone; this equates to approximately 500,000 women being affected by PPD annually.  


PPD impacts the function and quality of life of the patient and can have profound negative effects on the maternal-infant bond and infant development. PPD is symptomatically similar to an episode of major depression. However, the timing of its onset has led to its recognition as a distinct illness.  

Have you given birth? You may qualify for a postpartum depression research study.


Why Participate in the BLOOM Study?

The BLOOM Study (Brexanolone Lifting Outcomes Of Moms) focuses on postpartum depression (PPD), which is a significant and unmet healthcare need. If you are experiencing PPD, you may qualify for a study evaluating a new treatment. Current therapies are often limited, and some take a long time to show results, leaving many women without effective relief. Participating in this study is important, as postpartum depression remains a significant maternal mental health concern affecting many women after childbirth.  


Current treatments for postpartum depression (PPD) are limited, often delayed, and can cause side effects, leaving many women without adequate relief. The Bloom Study is researching innovative treatment options for postpartum depression that may provide a more convenient and accessible experience for mothers. With treatment that can be self-administered at home, the study aims to help advance future care options that support mothers and families. PPD, similar to major depression, occurs after childbirth and includes symptoms like sadness, loss of interest, difficulty concentrating, feelings of worthlessness, and suicidal thoughts.    


Study participants may earn financial compensation for time and travel. 

Study Criteria

Eligibility Requirements: 

  • Women who recently gave birth within the last 18 months
  • Currently experiencing severe depressive symptoms confirmed by a clinical interview
  • Experiencing depression symptoms that started late in pregnancy or shortly after giving birth
  • If needed, availability of at least one adult caregiver to assist with childcare for 72 hours after treatment begins


Current or Recent Treatment: 

  • If on therapy or antidepressants, treatment must be stable for at least 30 days before screening
  • If you recently stopped medication (within 30 days), you may still be eligible (study doctor will decide)
  • Participants will receive the study drug every 8 hours for 48 hours (7 doses in total) that can be self-administered from home

Join Our Study Today!

Study Locations

Click Your State to Contact a Local Lipocine Research Center

Tucson, AZ

Canoga Park, CA

Walnut Creek, CA

Aurora, CO

Atlanta, GA

Decatur, GA

Idaho Falls, ID

Chicago, IL

Wichita, KS

New Orleans, LA

Bloomfield Hills, MI

Chapel Hill, NC

Princeton, NJ

Las Vegas, NV

Manhattan, NY

League City, TX

Plano, TX

Richardson, TX

Clinton, UT

Orem, UT

Charlottesville, VA

 

Copyright © 2026 thebloomstudy.com - All Rights Reserved. 

Lpcn 1154-26-002


Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept